PDF DatasheetAntibody (Suitable for clinical applications)
| Specification | Recommendation |
|---|---|
| Recommended Dilution (Conc) | 1:25-1:75 |
| Pretreatment | Citrate Buffer pH 6.0 |
| Incubation Parameters | 30 min at Room Temperature |
Prior to use, inspect vial for the presence of any precipitate or other unusual physical properties. These can indicate that the antibody has degraded and is no longer suitable for patient samples. Please run positive and negative controls simultaneously with all patient samples to account and control for errors in laboratory procedure. Use of methods or materials not recommended by enQuire Bio including change to dilution range and detection system should be routinely validated by the user.
Cytokeratin 16 Information for Pathologists
Summary:
Molecular weight of 48 kDa. Paired with keratin 6. Activated keratinocytes produce keratin 6, 16, 17, not normally present (Am J Pathol 1998;152:1133). Upregulated in benign keratinocyte hyperplasia, including psoriasis; prepsoriatic skin may be converted to a distinct adult tissue type resembling hard palate (J Investig Dermatol Symp Proc 2006;11:16). Also upregulated in stress incontinence in periurethral vaginal wall (Hum Reprod 2006;21:22), conjunctival epithelium in Sjogrens syndrome (Exp Eye Res 2003;77:17).
Common Uses By Pathologists:
No significant clinical use by pathologists. Positive staining – normal Esophagus. Hair, nail and glands of epidermis. Melanocytes (Am J Dermatopathol 2005;27:476).
| Cytokeratin 16 General Information | |
|---|---|
| Alternate Names | |
| Molecular Weight | |
| 51.3 kDa | |
| Chromosomal Location | |
| q21.2 [chr: 17] [chr_start: 41609778] [chr_end: 41615899] [strand: -1] | |
| Curated Database and Bioinformatic Data | |
| Gene Symbol | KRT16 |
| Entrez Gene ID | 3868 |
| RefSeq Protein Accession(s) | NP_005548 |
| RefSeq mRNA Accession(s) | ; NM_005557 |
| RefSeq Genomic Accession(s) | NG_008301; NC_000017 |
| UniProt ID(s) | P08779 |
| PharmGKB ID(s) | PA30210 |
| KEGG Gene ID(s) | hsa:3868 |
| Associated Diseases (KEGG IDs) | Pachyonychia congenita 1 (PC1) [MIM:167200]: An autosomal dominant ectodermal dysplasia characterized by hypertrophic nail dystrophy resulting in onchyogryposis (thickening and increase in curvature of the nail), palmoplantar keratoderma, follicular hyperkeratosis, and oral leukokeratosis. Hyperhidrosis of the hands and feet is usually present. {ECO:0000269|PubMed:10521820, ECO:0000269|PubMed:10606845, ECO:0000269|PubMed:10839714, ECO:0000269|PubMed:11359398, ECO:0000269|PubMed:11886499, ECO:0000269|PubMed:16250206, ECO:0000269|PubMed:17719747, ECO:0000269|PubMed:21160496, ECO:0000269|PubMed:21326300, ECO:0000269|PubMed:22668561, ECO:0000269|PubMed:24118415, ECO:0000269|PubMed:7539673}. The disease is caused by mutations affecting the gene represented in this entry.; Keratoderma, palmoplantar, non-epidermolytic, focal 1 (FNEPPK1) [MIM:613000]: A dermatological disorder characterized by non-epidermolytic palmoplantar keratoderma limited to the pressure points on the balls of the feet, with later mild involvement on the palms. Oral, genital and follicular keratotic lesions are often present. {ECO:0000269|PubMed:8595410}. The disease is caused by mutations affecting the gene represented in this entry.; KRT16 and KRT17 are coexpressed only in pathological situations such as metaplasias and carcinomas of the uterine cervix and in psoriasis vulgaris. |
| General Description of Cytokeratin 16 . | |
| This antibody is specific to a 48 kDa protein, which is identified as cytokeratin 16. Cytokeratin 16 is expressed in keratinocytes, which are undergoing rapid turnover in the suprabasal region. High concordance was found between the carcinomas immunostaining with the basal cell and the hyperproliferation-related keratins. | |
There are no reviews yet.